In NSCLC, PLK1 inhibition-induced PD-L1 upregulation is driven by the MAPK pathway, as inhibition of ERK1/2 abolished the observed PD-L1 upregulation by volasertib. Here, PLK1 is linked to non-small cell lung carcinoma.